Back

Potentially good news for people living with MS. Biosimilars are usually more affordable than the original drug.

"The U.S. Food and Drug Administration recently approved Tyruko® (natalizumab-sztn, Sandoz), making it the first biosimilar disease-modifying therapy for adults living with relapsing forms of MS. Tyruko, which is similar to Tysabri, is expected to be made available during the first half of 2024."

https://www.nationalmssociety.org/About-the-Society/News/FDA-Approves-Tyruko%c2%ae,-Biosimilar-to-Tysabri%c2%ae,-for